已关闭
收藏All biotherapeutics have the potential to trigger an immune response, generating anti-drug antibodies (ADAs) that bind to different epitopes on the therapeutic protein. It is a regulatory expectation to monitor and characterise the ADAs specific to a biotherapeutic to evaluate efficacy and safety.
360biolabs offers a complete ADA determination process: